Consensus Article
Ajay Chhabra, Vk Dhandania, Sunil Mishra, Girish Parmar, Suneet Verma, Meenakshi Verma, Dk Singh, Jk Rath, Mk Bhadani, Pc Runnu, Jaikant Prasad, Akanksha Sonkar, Sanjay Kalra
Diabetes & Endocrinology
Sodium-glucose co-transporter 2 (SGLT2) inhibitors represent a major advancement in the pharmacological management of type 2 diabetes mellitus (T2DM), with robust evidence demonstrating benefits beyond glycemic control. They offer additional health b....
READ MORE
|
Letter To Editor
Jeyakantha Ratnasingam
The glucagon-like peptide-1 receptor agonist semaglutide has significantly revolutionized the landscape of management of obesity and related comorbidities including type 2 diabetes. One of the key features of semaglutide is the need for a gr....
READ MORE
|